Merit Medical Q1 Net Income Hits $56.7M, Viewpoint Deal Triples Oncology Market
Merit Medical reported Q1 net income of $56.7 million, or $0.94 per share, up from $52.9 million, while losing $1.5 million in sales due to shipping disruptions. The Viewpoint Medical acquisition, dilutive by $0.05, is projected to triple its oncology procedure market and boost its Resilience esophageal stent platform.
1. Q1 Financial Performance
Merit Medical posted Q1 revenue of $381.9 million and net income of $56.7 million, or $0.94 per share, compared with $52.9 million, or $0.86 per share, in the prior year. Adjusted EPS matched guidance at $0.94, reflecting steady demand across its disposable medical device portfolio.
2. Supply Chain and Tariff Challenges
A recall in the cardiac business was deemed immaterial to 2026 results, but geopolitical tensions in the Middle East led to $1.5 million in lost revenue from shipping delays. The company has initiated reimbursement for $15 million in tariffs and remains optimistic that final impact will decline if current conditions hold.
3. Acquisition and Product Outlook
The Viewpoint Medical acquisition, dilutive by $0.05 to non-GAAP EPS, is expected to expand the annual addressable oncology procedure market by approximately threefold, with projected sales growth of at least 20% annually and strong gross margins. Additionally, the Resilience Through the Scope esophageal stent launch targets a new growth avenue in the U.S. endoscopy market.